TAK Form 144: 34.9K ADS Insider Sale Signals Minor Impact

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (NYSE: TAK) has filed a Form 144 indicating a proposed insider sale of American Depositary Shares (ADSs) under Rule 144.

• Securities to be sold: 34,857 ADSs.
• Estimated market value: US$537,494.94.
• Broker: Interactive Brokers LLC, Greenwich, CT.
• Approximate sale date: 09 July 2025.
• Shares outstanding: 123,490,548 ADSs – the planned sale represents roughly 0.028% of the float.
• Source of shares: Vested Restricted Stock Unit awards acquired 01 July 2025 as compensation.

No other securities have been sold by the filer in the past three months and the filer affirms the absence of undisclosed adverse information. As this notice covers a relatively small position and involves previously issued shares, it does not affect Takeda’s share count or capital structure. Investors typically view Form 144 filings as neutral-to-slightly-negative sentiment indicators because they reflect potential insider selling, but the immaterial size here limits market impact.

Insights

Securities Analyst

TL;DR: Small insider sale (0.028% float) via Form 144 appears immaterial; sentiment modestly negative but no balance-sheet impact.

Form 144 filings alert the market to upcoming sales of restricted or control securities. The disposal of 34,857 ADSs worth ~US$537k is negligible versus Takeda’s ~123.5 million ADS float and multi-billion-dollar market cap. Because the shares stem from recently vested RSUs, the sale is likely routine for tax/liquidity purposes rather than a view on fundamentals. No new shares are being issued, so dilution is zero. Overall impact on valuation or liquidity should be minimal, yet some investors may read any insider sale as a slight negative signal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/09/2025 - 06:23 AM Learn about SEC filing dates

FAQ

How many Takeda (TAK) ADSs are being sold according to the Form 144?

34,857 ADSs are slated for sale.

What is the estimated market value of the securities listed in Takeda's Form 144?

Approximately US$537,494.94 based on the filing.

When is the planned sale date for the Takeda ADSs?

The filing lists an approximate sale date of 07/09/2025.

What percentage of Takeda's outstanding ADSs does the proposed sale represent?

Roughly 0.028% of the 123,490,548 ADSs outstanding.

Where did the shares originate?

They were vested Restricted Stock Units acquired on 07/01/2025 as compensation.

Will this Form 144 filing dilute existing Takeda shareholders?

No. The filing involves already-issued shares; no new shares are created.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	34857	537494.94	123490548	07/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2025	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			68656	07/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)